Recombinant factor VIIa in massive postpartum haemorrhage

International Journal of Obstetric Anesthesia

Volumn 16, Issue 1, 2007, Pages 29-34

  Karalapillai, D ^a   Popham, P ^a  

^a ROYAL WOMEN'S HOSPITAL   (Australia)

Author keywords

Anaesthesia; Factor VIIa; Obstetrics; Postpartum haemorrhage

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; HEMOSTATIC AGENT; HEPARIN; IDRAPARINUX; MELAGATRAN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; UTEROTONIC AGENT;

ANESTHESIA; ARTERY DISEASE; ARTERY THROMBOSIS; BLEEDING; BLOOD TRANSFUSION; DEEP VEIN THROMBOSIS; DRUG SAFETY; FETUS MORTALITY; FEVER; HEADACHE; HEART INFARCTION; HEMOPHILIA; HUMAN; JEHOVAH'S WITNESS; LUNG EMBOLISM; MATERNAL MORBIDITY; MATERNAL MORTALITY; MEDICAL LITERATURE; MORBIDITY; NONHUMAN; OBSTETRIC HEMORRHAGE; POSTPARTUM HEMORRHAGE; REVIEW; SKIN ALLERGY; THROMBOSIS; UTERINE ATONY; VOMITING;

COAGULANTS; FACTOR VII; FEMALE; HUMANS; JEHOVAH'S WITNESSES; OBSTETRIC SURGICAL PROCEDURES; POSTPARTUM HEMORRHAGE; PREGNANCY; RECOMBINANT PROTEINS; TIME FACTORS; UTERINE INERTIA;

EID: 33845458346     PISSN: 0959289X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijoa.2006.09.001     Document Type: Review

References (47)

1. Hedner U., and Erhardsten E. Potential role of rFVIIa in transfusion medicine. Transfusion 42 (2002) 114-124
2. Kenet G., Walden R., Eldad A., and Martinowitz U. Treatment of traumatic bleeding with recombinant factor VIIa. Lancet 354 (1999) 1879
3. Martinowitz U., Kenet G., Segal E., et al. Recombinant activated factor VII for adjunctive hemorrhage control in trauma. J Trauma 51 (2001) 431-438
4. Moscardo F., Perez F., de La Rubia J., et al. Successful treatment of severe intra-abdominal bleeding associated with disseminated intravascular coagulation using recombinant activated factor VII. Br J Haematol 114 (2001) 174-176
5. Hendriks H., van der Maaten D., de Wolf J., et al. An effective treatment of severe intractable bleeding after valve repair by one single dose of activated recombinant factor VII. Anesth Analg 93 (2001) 287-289
6. Friedrich P.W., Geerdink M.G., Spatoro M., et al. The effect of administration of recombinant factor VIIa on perioperative blood loss in patients undergoing transabdominal retropubic prostatectomy: The PROSE study. Blood Coagul Fibrinolysis 11 (2000) S129-S132
7. Kalicinski P., Kaminski A., Drewniak H., et al. Quick correction of hemostasis in two patients with fulminant liver failure undergoing liver transplantation by recombinant activated factor VII. Transf Proc 31 (1999) 375-379
8. Shami V.M., Caldwell S.S., Hespenheide E.E., et al. Recombinant activated factor VII for coagulopathy in fulminant hepatic failure compared with conventional therapy. Liver Transpl 9 (2003) 138-143
9. Why mothers die. A Report on the Confidential Enquiries into Maternal Deaths in the United Kingdom, 1994-1996 (1998), Department of Health, HMSO, London
10. Why mothers die. Report on Confidential Enquiries into Maternal Deaths in the United Kingdom, 2000-2002 (2004), RCOG Press, London
11. Drife J. Management of primary post partum haemorrhage. Br J Obstet Gynaecol 104 (1997) 275-277
12. Macphail S., and Talks K. Massive post partum haemorrhage and management of disseminated intravascular coagulation. Curr Obstet Gynecol 14 (2004) 123-131
13. Mousa H., and Walkinshaw S. Major post partum haemorrhage. Curr Opin Obstet Gynecol 13 (2001) 595-603
14. Ahonen J., and Jokela R. Recombinant factor VIIa for life-threatening post-partum haemorrhage. Br J Anaesth 94 (2005) 592-595
15. Boehlen F., Morales M.A., Fontana P., Ricou B., Irion O., and Moerloose P. Prolonged treatment of massive postpartum haemorrhage with recombinant factor VIIa: case report and review of the literature. Br J Obstet Gynaecol 111 (2004) 284-287
16. Bouwmeester F.W., Jonkhoff A.R., Verheijen R., and van Geijn H. Successful treatment of life threatening postpartum hemorrhage with recombinant activated factor VII. Obstet Gynecol 101 (2003) 1174-1176
17. Gidiri M., Noble W., Rafique Z., Patil K., and Lindow S. Caeserean section for placenta praevia complicated by postpartum haemorrhage managed successfully with recombinant activated human coagulation factor VIIa. J Obstet Gynecol 24 (2004) 925-926
18. Haynes J, Laffan M, Plaat F. Use of recombinant activated factor VII in massive obstetric haemorrhage. Int J Obstet Anesth (in press).
19. Price G., Kaplan J., and Skowronski G. Use of recombinant factor VIIa to treat life-threatening non-surgical bleeding in a post partum patient. Br J Anaesth 93 (2004) 298-300
20. Segal S., Shemesh I.Y., Blumenthal R., et al. Treatment of obstetric hemorrhage with recombinant activated factor VII (rFVIIa). Arch Gynecol Obstet 268 (2003) 266-267
21. Zupancic Salek S., Sokolic V., Viskovic T., Sanjug J., Simic M., and Kastelan M. Successful use of recombinant factor VIIa for massive bleeding after caesarean section due to HELLP syndrome. Acta Haematol 108 (2002) 162-163
22. Erber W., and Perry D. Plasma and plasma products in the treatment of massive haemorrhage. Best Pract Clin Haematol 19 (2006) 97-112
23. Banninger H., Lammle B., and Furlan M. Binding of alpha-thrombin to fibrin depends on the quality of the fibrin network. Biochem J 298 (1994) 157-163
24. Blomback B., Carlsson K., Fatah K., Hessel B., and Procyk R. Fibrin in the human plasma gel architectures governed by rate and nature of fibrinogen activation. Thromb Res 75 (1994) 521-538
25. Gabriel D., Muga K., and Boothroyd E. The effect of fibrin structure on fibrinolysis. J Biol Chem 267 (1992) 259-263
26. Mittal S., and Watson H. A critical appraisal of the use of recombinant factor VIIa in acquired bleeding conditions. Br J Haematol 133 (2006) 355-363
27. McCall P., Story D., and Karalapillai D. Audit of factor VIIa for bleeding resistant to conventional therapy following complex cardiac surgery. Can J Anaesth 53 (2006) 926-933
28. Boffard K., Riou B., Warren B., et al. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. J Trauma 59 (2005) 8-15
29. Clark A.D., Gordon W.C., Walker I.D., and Tait R.C. 'Last-ditch' use of recombinant factor VIIa in patients with massive haemorrhage is ineffective. Vox Sang 86 (2004) 120-124
30. NovoSeven™ product information, Novo Nordisk Pharmaceuticals: Copenhagen, Denmark.
31. Stainsby D., MacLennan S., and Hamilton P. Management of massive blood loss: a template guideline. Br J Anaesth 85 (2000) 487-491
32. Martinowitz U., and Michaelson M. Guidelines for the use of transfusion factor VII in uncontrolled bleeding: a report by the Israeli Multidisciplinary taskforce. J Thromb Haemost 3 (2005) 640-648
33. Levi M., Peters M., and Buller H. Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review. Crit Care Med 33 (2005) 883-890
34. Thompson A. When all else fails to stop massive bleeding from trauma. J Thromb Haemost 3 (2005) 638-639
35. Meng Z., Wolberg A., Monroe D., and Hoffman M. The effect of temperature and pH on the activity of factor VIIa: implications for the efficacy of high dose factor VIIa in hypothermic acidotic patients. J Trauma 55 (2003) 886-891
36. Franchini M., Zaffanello M., and Vaneri D. Recombinant factor VIIa. An update on its clinical use. Thromb Haemost 93 (2005) 1027-1035
37. Mitty H.A., Sterling K.M., Alvarez M., and Gendler R. Obstetric hemorrhage: prophylactic and emergency arterial catheterization and embolotherapy. Radiology 188 (1993) 183-187
38. Tamizian O., and Arulkumaran S. The surgical management of post-partum haemorrhage. Best Pract Res Clin Obstet Gynaecol 16 (2002) 81-98
39. Shamsi T.S., Hossain N., Soomro N., et al. Use of recombinant factor VIIa for massive postpartum haemorrhage: case series and review of the literature. J Pak Med Assoc 55 (2005) 512-515
40. Spahn D., Tucci M., and Makris M. Is recombinant factor VIIa the magic bullet in the treatment of major bleeding?. Br J Anaesth 94 (2005) 553-555
41. Milligan L., and Bellamy M. Anaesthesia and critical care of Jehovah's witnesses. Br J Anaesth (CEACCP) 4 (2004) 33-35
42. Aledort L. rFVIIa: Its thrombogenicity. Thromb Haemost 84 (2000) 522-523
43. Peerlinck K., and Vermylen J. Acute myocardial infarction following administration of recombinant activated factor VII (Novo Seven) in a patient with haemophilia A and inhibitor. Thromb Haemost 82 (1999) 1775-1776
44. Roberts H. Clinical experience with activated factor VII: focus on safety aspects. Blood Coagul Fibrinolysis 9 (1998) S115-S118
45. Siegel L., Gerig L., Tuttenberg J., Demple C., Scharf J., and Fiedler F. Cerebral sinus thrombosis in a trauma patient after recombinant activated factor VII infusion. Anesthesiology 100 (2004) 441-443
46. Biss T.T., and Hanley J.P. Recombinant activated factor VII (rFVIIa/NovoSeven®) in intractable haemorrhage: use of a clinical scoring system to predict outcome. Vox Sang 90 (2006) 45-52
47. Aledort L.M. Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity. J Thromb Haemost 2 (2004) 1700-1708